Viridian Therapeutics, Inc. (VRDN)

♥ 439 Thanks from members

Viridian Therapeutics, Inc. (VRDN) is experiencing mixed market sentiment, marked by a recent 22% cut in analyst revenue estimates, intermittent selling pressure, and volatile price action testing key technical support levels.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology & Pharmaceuticals Founder: Viridian Therapeutics Team Leadership: Susan Stewart (CEO) Leadership: Barrie J. Levitt (Chief Medical Officer) Holder: Fidelity Management & Research Holder: BlackRock Inc. Holder: RA Capital Management VRDN-001 VRDN-003 IGF-1R Inhibitors for Thyroid Eye Disease #VRDN #Viridian Therapeutics #NASDAQ VRDN #Biotech Stock #Thyroid Eye Disease